PD 168368 is a NMBR (Neuromedin B) antagonist displaying ~40-fold selectivity over GRP-R, BB2 and >300-fold selectivity over BRS-R. Antagonizes neuromedin B-stimulated Ca2+ release and inhibits proliferation of rat glioma cells.
1. Ryan, R R., et al., 1999. Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. The Journal of pharmacology and experimental therapeutics. 290(3): 1202-11. PMID: 10454496 2. Moody, T W., et al., 2000. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. European journal of pharmacology. 409(2): 133-42. PMID: 11104826 3. Moody, Terry W., et al., 2003. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. European journal of pharmacology. 474(1): 21-9. PMID: 12909192 4. Park, H.J. et al. 2011. Cancer Lett. 312(1): 117-127. PMID: 21908103
It is recommend to use solutions containing sc-204166 within the same day they are made. To store a solution, aliquot into usable amounts and store at -20°C for up to two weeks.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
ParkPark, HJ. et al. (PubMed 21908103) reported that the Neuromedin B receptor antagonist, PD 168368, suppresses tumor angiogenesis and tumor growth in vitro and in vivo. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn